NM 402
Alternative Names: NM-402Latest Information Update: 26 Apr 2023
At a glance
- Originator Neuramedy; Yungjin Pharm Co
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Alpha-synuclein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple system atrophy
Most Recent Events
- 13 Apr 2023 Early research in Multiple system atrophy in South Korea (unspecified route) (Neuramedy pipeline, April 2023)